speci
zair
ebola
viru
member
genu
ebola
viru
famili
filovirida
consid
signific
public
health
concern
due
high
fatal
rate
human
infect
caus
ebola
viru
diseas
evd
lethal
acut
hemorrhag
diseas
past
year
ebola
viru
diseas
outbreak
african
countri
record
largescal
epidem
broke
western
africa
death
confirm
recent
evd
epidem
report
democrat
republ
congo
first
report
may
develop
antiebov
agent
hamper
partli
due
biosafeti
level
contain
requir
handl
infecti
ebola
viru
three
type
antiebola
agent
report
potenti
prophylact
andor
therapi
ebola
viru
infect
vaccin
antibodi
potenti
vaccin
monoclon
antibodi
cocktail
zmapp
shown
highli
effect
protect
nonhuman
primat
lethal
ebola
viru
infect
small
molecul
inhibitor
either
target
viral
protein
includ
rna
polymeras
inhibitor
favipiravir
remdesivir
protein
inhibitor
glycoprotein
host
protein
differ
nucleic
acid
sirna
antisens
morpholin
substitut
oligonucleotid
report
potenti
antiebola
agent
ebola
viru
glycoprotein
gp
viral
surfac
protein
sole
respons
receptor
bind
mediat
fusion
viral
host
membran
viral
entri
gp
compos
heterodim
form
trimer
gp
consid
promis
target
antiebola
drug
develop
inhibitor
could
block
viral
entri
cell
first
step
viru
replic
antibodybas
therapi
work
block
step
inhibitor
list
figur
identifi
antiebov
activ
possibl
via
target
gp
none
approv
therapeut
human
clinic
trial
identifi
develop
new
antiebov
agent
evalu
small
librari
diarylquinolin
compound
supplementari
tabl
previous
shown
antituberculosi
activ
antiebola
viru
entri
abil
found
compound
potent
entri
inhibitor
ebola
viru
entri
result
subsequ
viral
replic
human
lung
epitheli
cell
line
atcc
manassa
va
usa
human
embryon
kidney
cell
line
atcc
manassa
va
usa
african
green
monkey
vero
cell
atcc
manassa
va
usa
hela
cell
line
atcc
manassa
va
usa
cultur
dulbecco
modifi
eagl
medium
dmem
cellgro
manassa
va
usa
supplement
fetal
bovin
serum
fb
gibco
carlsbad
ca
usa
streptomycin
unit
penicillin
invitrogen
carlsbad
ca
usa
three
type
recombin
pseudovirus
use
studi
contain
correspond
viral
membran
glycoprotein
gp
plasmid
contain
gpencod
gene
use
influenza
viru
ha
na
lasvgp
ebovgp
core
plasmid
plasmid
transient
transfect
cell
confluenc
use
polyethyleniminebas
transfect
protocol
h
cell
wash
pb
buffer
replac
ml
clear
medium
cultur
dish
mm
supernat
collect
h
later
pass
millipor
filter
nalgen
rochest
ny
usa
stock
use
obtain
small
librari
quinolin
compound
potent
antitubercular
activ
dr
huaq
cui
peke
union
medic
colleg
chines
academi
medic
scienc
beij
china
structur
inform
compound
provid
supplementari
tabl
compound
dissolv
dmso
store
stock
concentr
mm
cell
seed
plate
cell
per
well
one
day
infect
pseudovirus
compound
ad
well
togeth
virus
final
concentr
dmso
plate
incub
h
luciferas
activ
infect
cell
quantifi
neolit
report
gene
detect
system
perkinelm
waltham
usa
cat
well
treat
virus
alon
dmso
use
neg
control
well
treat
virus
togeth
hiv
revers
transcriptas
inhibitor
azidothymidin
azt
use
posit
control
compound
test
duplic
cell
viabil
measur
cell
perform
h
treatment
compound
dmso
control
dmem
supplement
fb
use
celltiterglo
kit
promega
madison
wi
usa
hit
compound
twofold
serial
dilut
total
concentr
doserespons
titrat
calcul
prism
softwar
edit
graphpad
softwar
la
jolla
ca
usa
assay
perform
replic
well
repeat
twice
use
similar
dock
method
report
previou
public
briefli
glide
modul
portland
usa
within
suit
use
rank
best
conform
orient
ligand
base
interact
ebola
viru
gp
pdb
code
ligprep
includ
ioniz
modul
macromodel
modul
use
gener
threedimension
coordin
ligand
protein
calcul
ioniz
state
grid
file
center
toremifen
caviti
gp
produc
dock
conform
flexibl
ligand
handl
via
exhaust
conform
search
topscor
conform
visual
use
ucsf
chimera
version
univers
california
san
francisco
san
francisco
ca
usa
cell
plate
cell
per
well
incub
pseudovirion
h
supernat
remov
well
cell
wash
twice
pb
buffer
fresh
dmem
ad
cell
cell
incub
incub
differ
time
point
compound
ad
final
concentr
experi
perform
triplic
well
use
benztropin
control
viru
infect
quantifi
luciferas
signal
h
infect
time
point
data
normal
valu
dmso
vehicletr
control
well
infecti
ebola
viru
assay
perform
biosafeti
level
facil
texa
biomed
research
institut
usa
infecti
ebov
produc
previous
describ
ebov
mayinga
isol
ebovgfp
genbank
use
assay
heinz
feldmann
nih
rocki
mountain
laboratori
hamilton
mt
usa
contain
insert
green
fluoresc
protein
gfp
nucleoprotein
np
viru
grown
vero
cell
day
cultur
supernat
contain
virus
centrifug
sucros
cushion
g
h
viru
pellet
suspend
pb
buffer
store
aliquot
use
infect
assay
hela
cell
first
seed
tissu
cultur
plate
cell
per
well
cultur
overnight
dmem
medium
fb
next
cell
infect
ebovgfp
viru
moi
presenc
test
compound
variou
concentr
bafilomycin
use
posit
control
concentr
test
duplic
h
incub
postinfect
cell
fix
ad
formalin
h
fixat
formalin
remov
plate
wash
twice
pb
buffer
cell
nuclei
stain
hoechst
dye
cat
number
thermo
fisher
scientif
waltham
usa
blue
fluoresc
cell
nuclei
blue
green
fluoresc
infect
cell
express
gfp
imag
fluoresc
microscopi
number
cell
nuclei
infect
cell
count
use
cellprofil
softwar
version
broad
institut
cambridg
usa
total
number
nuclei
blue
use
check
cell
function
reduct
indic
growth
arrest
toxic
note
analysi
although
still
fda
approv
therapi
human
use
sever
antiebov
drug
develop
research
show
antimicrobi
agent
includ
antimalari
also
report
reason
antivir
activ
bedaquilin
fda
approv
second
line
antituberculosi
drug
specif
use
treat
multidrugresist
tuberculosi
mdrtb
studi
screen
small
librari
bedaquilin
deriv
potenti
novel
ebola
viru
entri
inhibitor
use
pseudotyp
entri
assay
three
type
pseudovirus
simultan
use
initi
screen
reduc
fals
posit
identifi
ebolaspecif
entri
inhibitor
mani
quinolin
compound
show
strong
inhibit
ebov
entri
supplement
tabl
compound
antiebov
activ
specif
inhibit
host
cell
viabil
select
evalu
result
list
tabl
compound
inhibit
entri
either
wherea
display
inhibit
ebola
gpmediat
entri
final
concentr
nontox
cell
cell
viabil
concentr
select
compound
pseudoviru
entri
determin
rang
tabl
compound
rang
indic
compound
toxic
host
cell
calcul
si
valu
compound
compound
potent
inhibitor
among
compound
si
valu
explor
mechan
action
moa
compound
inhibit
ebola
viru
entri
timeof
addit
toa
experi
perform
follow
previous
publish
protocol
use
benztropin
posit
control
report
ebov
entri
inhibitor
interf
gpmediat
fusion
viru
membran
host
endosom
membran
result
figur
show
benztropin
compound
similarli
block
viral
entri
well
within
one
hour
gradual
lost
activ
afterward
suggest
compound
like
benztropin
block
ebola
gpmediat
viral
entri
endosom
antiviru
effect
compound
evalu
valid
hela
cell
infecti
ebov
infect
facil
highcont
imag
detect
method
ebola
mayinga
isol
use
studi
compound
effect
block
replic
infecti
ebov
figur
consist
result
pseudoviru
entri
assay
sinc
compound
hela
cell
figur
select
index
si
compound
although
still
fda
approv
therapi
human
use
sever
class
antiebov
drug
preclin
clinic
develop
includ
limit
antihistamin
antimuscarin
estrogen
receptor
antagonist
calciumchannel
blocker
topic
anesthet
select
serotonin
reuptak
inhibitor
studi
screen
small
librari
bedaquilin
fda
approv
second
line
antituberculosi
drug
deriv
identif
potenti
novel
ebola
viru
entri
inhibitor
use
pseudotyp
entri
assay
librari
contain
bedaquilin
analog
inhous
librari
dr
huaq
cui
peke
union
medic
colleg
chines
academi
medic
scienc
beij
china
structureact
relationship
sar
analysi
diaryquinolin
analog
supplement
tabl
summar
figur
highlight
key
substitut
quinolin
core
activ
compound
contain
termin
basic
amin
side
chain
exemplifi
bear
dimethylamino
methyl
phenyl
chain
compound
less
basic
amin
chain
amid
pyrazol
predict
pka
less
potent
ebov
suggest
pka
termin
chain
essenti
activ
inhibitor
substitut
show
better
potenc
compar
heterocycl
simpl
methoxi
group
aryl
substitut
quinolin
requir
good
antiebov
activ
quinolin
toler
simpl
hydrogen
halogen
group
screen
addit
evalu
need
dissect
role
region
ebov
activ
evalu
bind
posit
toremifen
bind
pocket
ebov
gp
use
molecular
dock
optim
conform
compound
highli
overlap
toremifen
predict
engag
similar
residu
bind
pocket
figur
core
form
paralleldisplac
interact
figur
explain
enhanc
activ
chemic
scaffold
ebov
termin
nitrogen
n
tail
compound
form
strong
electrostat
interact
within
consist
sar
analysi
termin
basic
amin
side
chain
chain
extend
ethyl
chlorid
pocket
toremifen
interact
extra
hydrophob
interact
region
shown
interact
ligand
newer
publish
crystal
structur
eg
structur
ebov
gp
complex
benztropin
pdb
code
overal
predict
highli
fit
toremifenebind
pocket
potenti
explain
good
potenc
compound
studi
use
pseudotyp
viru
screen
platform
evalu
small
librari
diarylquinolin
compound
identifi
number
ebola
virusspecif
entri
inhibitor
potent
inhibitor
seri
compound
use
pseudotyp
viru
use
infecti
ebola
viru
timeofaddit
toa
experi
comput
dock
studi
support
notion
compound
like
bind
caviti
ebola
gp
toremifen
small
molecul
inhibitor
block
gpmediat
entri
structureact
relationship
sar
analysi
suggest
medicin
chemistri
option
improv
potenc
seri
inhibitor
therefor
think
scaffold
optim
develop
antiebov
therapeut
addit
antiebov
activ
also
inhibit
lasv
entri
though
dramat
observ
ebov
suggest
might
also
affect
endosom
traffick
could
investig
potenti
broadspectrum
antivir
via
modul
endosom
traffick
futur
numer
small
molecul
therapeut
candid
directli
target
ebov
gp
critic
host
factor
viral
entri
report
inhibitor
target
event
occur
endosom
gp
proteolyt
process
endosom
traffick
interact
fusion
includ
fydmk
cathepsin
b
l
inhibitor
inhibitor
target
host
factor
late
endosom
step
ebov
entri
target
numer
ltype
calcium
channel
inhibitor
includ
verapamil
tetrandrin
nimodipine
diltiazem
group
select
estrogen
receptor
modul
serm
clomiphen
toremifen
directli
bind
ebola
gp
numer
gprotein
coupl
receptor
gpcr
antagonist
antihistamin
target
ebola
viru
marburg
viru
gp
first
gener
antihistamin
diphenhydramin
chlorcyclizin
effect
block
entri
ebola
viru
marburg
virus
consist
notion
compound
exert
antivir
effect
endosom
number
serm
toremifen
gpcr
antagonist
benztropin
shown
bind
pocket
subunit
interfac
ebola
gp
analysi
bind
pocket
provid
insight
mechan
divers
scaffold
small
molecul
inhibit
entri
ebola
viru
insight
could
use
ration
drug
design
improv
potenc
inhibitor
shown
compound
although
structur
differ
serm
gpcr
antagonist
could
bind
pocket
ebola
gp
demonstr
via
dock
analysi
figur
c
suggest
similar
mechan
inhibit
measur
interact
protein
small
molecul
low
molecular
weight
help
evalu
candid
compound
choic
biophys
method
limit
far
thermal
shift
assay
appli
measur
interact
assay
need
ebola
glycoprotein
natur
conform
current
abl
obtain
howev
preliminari
sar
analysi
compound
analog
figur
reveal
path
forward
optim
inhibitor
potenti
drug
develop
